George A Stouffer

List of Publications by Citations

117 papers	1,580 citations	21 h-index	38 g-index
140 ext. papers	2,050 ext. citations	6.5 avg, IF	4.67 L-index

#	Paper	IF	Citations
117	Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction. *Circulation*, **2019**, 139, 1047-1056	16.7	175
116	Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *JACC: Cardiovascular Interventions*, **2018**, 11, 181-191	5	156
115	Accuracy of Cuff-Measured Blood Pressure: Systematic Reviews and Meta-Analyses. *Journal of the American College of Cardiology*, **2017**, 70, 572-586	15.1	109
114	Targeted repair of heart injury by stem cells fused with platelet nanovesicles. *Nature Biomedical Engineering*, **2018**, 2, 17-26	19	101
113	Therapeutic strategies for thrombosis: new targets and approaches. *Nature Reviews Drug Discovery*, **2020**, 19, 333-352	64.1	82
112	Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. *Circulation*, **2001**, 104, 582-7	16.7	67
111	A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization. *American Heart Journal*, **2005**, 150, 1204-11	4.9	66
110	Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 664-674	6.1	64
109	Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. *Circulation*, **2003**, 107, 2914-9	16.7	60
108	The Role of β3 Integrins in Vascular Healing. *Thrombosis and Haemostasis*, **2002**, 87, 187-193	7	44
107	Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase. *Catheterization and Cardiovascular Interventions*, **2005**, 66, 327-32	2.7	43
106	Clinical Outcomes and Sustainability of Using Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *Circulation Genomic and Precision Medicine*, **2018**, 11, e002069	5.2	41
105	Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. *Journal of Lipid Research*, **2016**, 57, 109-19	6.3	41
104	Impact of Type 2 Myocardial Infarction (MI) on Hospital-Level MI Outcomes: Implications for Quality and Public Reporting. *Journal of the American Heart Association*, **2018**, 7,	6	36
103	Association of inpatient vs outpatient onset of ST-elevation myocardial infarction with treatment and clinical outcomes. *JAMA - Journal of the American Medical Association*, **2014**, 312, 1999-2007	27.4	31
102	Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 647-652	9.4	29
101	Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. *Genetics in Medicine*, **2020**, 22, 160-169	8.1	28

100	Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. *Pharmacogenomics*, **2015**, 16, 303-13	2.6	27
99	Acute ST-elevation myocardial infarction in patients hospitalized for noncardiac conditions. *Journal of the American Heart Association*, **2013**, 2, e000004	6	25
98	CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. *Pharmacogenomics*, **2017**, 18, 1155-1166	2.6	24
97	Implementation of inpatient models of pharmacogenetics programs. *American Journal of Health-System Pharmacy*, **2016**, 73, 1944-1954	2.2	23
96	Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions. *Drugs*, **2011**, 71, 2009-30	12.1	21
95	Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. *Pharmacogenomics*, **2018**, 19, 1039-1046	2.6	18
94	Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease. *American Journal of Pathology*, **2017**, 187, 2895-2911	5.8	18
93	Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura. *Catheterization and Cardiovascular Interventions*, **2004**, 61, 364-7	2.7	18
92	In-Hospital ST-Segment Elevation Myocardial Infarction: Improving Diagnosis, Triage, and Treatment. *JAMA Cardiology*, **2018**, 3, 527-531	16.2	15
91	Predictors, treatment, and outcomes of STEMI occurring in hospitalized patients. *Nature Reviews Cardiology*, **2016**, 13, 148-54	14.8	14
90	The role of alpha(v)beta3 integrins in vascular healing. *Thrombosis and Haemostasis*, **2002**, 87, 187-93	7	12
89	Ratio of systolic blood pressure to left ventricular end-diastolic pressure at the time of primary percutaneous coronary intervention predicts in-hospital mortality in patients with ST-elevation myocardial infarction. *Catheterization and Cardiovascular Interventions*, **2017**, 90, 389-395	2.7	11
88	Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 726-732	9.4	11
87	Activation of protease-activated receptors 3 and 4 accelerates tissue factor-induced thrombin generation on the surface of vascular smooth muscle cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 2587-96	9.4	11
86	Causes and hemodynamic findings in chronic severe pulmonary regurgitation. *Catheterization and Cardiovascular Interventions*, **2018**, 92, E197-E203	2.7	10
85	Incidence and management of "no-reflow" following percutaneous coronary interventions. *American Journal of the Medical Sciences*, **2005**, 329, 78-85	2.2	9
84	CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002441	5.2	9
83	Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. *Prostaglandins and Other Lipid Mediators*, **2018**, 134, 24-31	3.7	9

82	Ultrafine particulate matter exposure impairs vasorelaxant response in superoxide dismutase 2-deficient murine aortic rings. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2018**, 81, 106-115	3.2	8
81	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 705-715	6.1	8
80	Angiographic severity does not correlate with fractional flow reserve in heavily calcified coronary arteries. *Catheterization and Cardiovascular Interventions*, **2017**, 89, 226-232	2.7	7
79	A Quality Improvement Program for Recognition and Treatment of Inpatient ST-Segment Elevation Myocardial Infarctions. *JAMA Cardiology*, **2016**, 1, 1077-1079	16.2	6
78	Influence of sex on the accuracy of oscillometric-derived blood pressures. *Journal of Clinical Hypertension*, **2011**, 13, 112-9	2.3	6
77	Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49). *American Journal of Cardiology*, **2020**, 125, 485-490	3	6
76	Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence. *Pharmacogenomics and Personalized Medicine*, **2020**, 13, 239-252	2.1	6
75	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in PCI. *JACC: Cardiovascular Interventions*, **2019**, 12, 1867	5	5
74	Identification of Factors Associated With Improved Survival After Renal Artery Stenting. *American Journal of Cardiology*, **2017**, 119, 664-668	3	5
73	Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction. *Drugs*, **2009**, 69, 1945-66	12.6	5
72	Hemodynamics of myocardial bridging. *Catheterization and Cardiovascular Interventions*, **2008**, 71, 590-3	2.7	5
71	Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients. *Pharmacogenomics*, **2020**, 21, 431-441	2.6	4
70	Correlation of infarct size with invasive hemodynamics in patients with ST-elevation myocardial infarction. *Catheterization and Cardiovascular Interventions*, **2018**, 92, E333-E340	2.7	4
69	The use of hemodynamics to predict mortality in patients undergoing primary PCI for ST-elevation myocardial infarction. *Expert Review of Cardiovascular Therapy*, **2018**, 16, 551-557	2.5	4
68	Is time of renal hypoperfusion an important variable in determining response to renal artery revascularization?. *JACC: Cardiovascular Interventions*, **2014**, 7, 110	5	4
67	Mechanical thrombectomy options in complex percutaneous coronary interventions. *Catheterization and Cardiovascular Interventions*, **2006**, 68, 917-28	2.7	4
66	Effects of Restoration of Blood Flow on the Development of Aortic Atherosclerosis in ApoE-/- Mice With Unilateral Renal Artery Stenosis. *Journal of the American Heart Association*, **2016**, 5, e002953	6	4
65	Recurrent anaphylaxis during cardiac catheterization due to ethylene oxide. *Journal of Allergy and Clinical Immunology: in Practice*, **2018**, 6, 2148-2150	5.4	4

64	Scintographic evidence of severe myocardial hypoperfusion in a patient with left anterior descending coronary artery bridging--case report and review of the literature. *American Journal of the Medical Sciences*, **2008**, 336, 498-502	2.2	3
63	Effect of multielement intravascular ultrasound on the anticoagulant potency of enoxaparin. *American Journal of Cardiology*, **2004**, 93, 1453-4, A12	3	3
62	Mechanisms of ST Elevation Myocardial Infarction in Patients Hospitalized for Noncardiac Conditions. *American Journal of Cardiology*, **2019**, 123, 1393-1398	3	2
61	Letter by Dai et al regarding article, "ST-elevation myocardial infarction diagnosed after hospital admission". *Circulation*, **2015**, 131, e6	16.7	2
60	Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2021**, 26, 533-549	2.6	2
59	Risk of developing coronary artery disease following a normal coronary angiogram in middle-aged adults. *Journal of Invasive Cardiology*, **2014**, 26, 624-8	0.7	2
58	Left Ventricular Thrombus Formation in the Setting of Normal Systolic Function. *JACC: Case Reports* , **2020**, 2, 1470-1474	1.2	1
57	Logistical Challenges Associated With Implementing Precision Medicine. *JAMA Cardiology*, **2019**, 4, 1300	16.2	1
56	Hemodynamics of renal artery stenosis. *Catheterization and Cardiovascular Interventions*, **2008**, 72, 121-4	2.7	1
55	Timing of surgery in aortic stenosis. *Current Treatment Options in Cardiovascular Medicine*, **2006**, 8, 421-7	2.1	1
54	Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.. *Journal of the American Heart Association*, **2022**, 11, e024159	6	1
53	Effect of Gender on Clinical Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *Circulation Genomic and Precision Medicine*, **2020**, 13, 554-556	5.2	1
52	Effect of government-issued state of emergency and reopening orders on cardiovascular hospitalizations during the COVID-19 pandemic. *American Journal of Preventive Cardiology*, **2021**, 6, 100172-100172	1.9	1
51	Ability of a novel shock index that incorporates invasive hemodynamics to predict mortality in patients with ST-elevation myocardial infarction. *Catheterization and Cardiovascular Interventions*, **2021**, 98, 87-94	2.7	1
50	Identifying Isolated Systolic Hypertension From Upper-Arm Cuff Blood Pressure Compared With Invasive Measurements. *Hypertension*, **2021**, 77, 632-639	8.5	1
49	Hemodynamic Findings of Severe Subacute Aortic Regurgitation. *Journal of Invasive Cardiology*, **2017**, 29, E74	0.7	1
48	Resting Pd/Pa correlates with fractional flow reserve but not angiographic severity in calcified coronary arteries. *Catheterization and Cardiovascular Interventions*, **2021**, 97, 625-631	2.7	0
47	In-hospital outcomes after switching from a bivalirudin-first strategy to an unfractionated heparin-first strategy for percutaneous coronary interventions. *Cardiovascular Diagnosis and Therapy*, **2018**, 8, 137-145	2.6	0

46 Hemodynamic and Intravascular Ultrasound Evaluation of an Infrarenal Aortic Stenosis. *JACC: Cardiovascular Interventions*, **2016**, 9, e11-e12 5

45 Pharmacological Therapy in the Management of Acute Coronary Syndromes **2015**, 517-531

10	Atrial Septal Defect Primum82-83	
9	Intracerebral Bleed128-129	
8	Introduction to ECG Interpretation1-2	
7	Application and interpretation of fractional flow reserve in heavily calcified coronary arteries **2022**, 61-69	
6	Length of Preprocedure Fasting Was Associated With Contrast Associated-Acute Kidney Injury in High-Risk Patients Undergoing Coronary Angiography. *American Journal of Cardiology*, **2021**, 159, 1-7	3
5	Expression of Cyr61 in ApoE mice with chronic unilateral renal artery ligation. *Scientific Reports*, **2021**, 11, 3606	4.9
4	An Update on Catheter-Based Renal Denervation for the Treatment of Hypertension. *Current Cardiovascular Risk Reports*, **2021**, 15, 1	0.9
3	Patients with Left Ventricular Thrombus Despite Normal Systolic Function. *American Journal of the Medical Sciences*, **2021**, 362, 198-206	2.2
2	Usefulness of a Novel Risk Score to Predict In-Hospital Mortality in Patients 60 Years of Age with ST Elevation Myocardial Infarction. *American Journal of Cardiology*, **2021**, 154, 1-6	3
1	Bezold-Jarisch Reflex **2022**, 1, 100029	